Preoperation and postoperation anti mullerian hormone levels in patients with endometrioma

Öz

Preoperation And Postoperation Anti Mullerian Hormone Levels In Patients With Endometrioma Objective: Anti-Mullerian Hormon (AMH) primarily roles in male sex diferantiation and is a member ofTransforming Growth Factor-b family Infemale it is secreted from the granulosa cells of the growingfollicle and suggested as an indicator of ovarian reserves. In our study our target is to point out if AMH levels changes in patients with endometrioma strippingprocedure. Material and Method: Study includes 47patients applied stripping because of endometrioma in GATA Obstetrics and Gynecology Clinic.(Study group). Patients, 33 with unilateral and 14 with bilateral endometrioma, are gathered among whose endometrioma dimensions are above 45mm. Ovarian endometrioma stripping procedure is executed to allpatient group. Results: No significant distinction was detected between the preoperative AMH levels of the patients with unilateral and bilateral endometrioma, compared with the control group (p=0.98 ve p=0.71). No significant differencewas detected between the two groups statistically (p=0.86). Conclusion: Our results show that preoperative AMH levels inpatients with endometrioma has no altering effect on follicular pool. In short term follow, endometrioma stripping procedure does not damage healthy, AMH secreting ovarian tissue.

Anahtar Kelimeler

• -

Ovarian endometriomalı hastalarda preoperatif ve postoperatif anti müllerin hormon seviyeleri

Öz

Amaç: Anti-Müllerian Hormon (AMH) primer olarak erkek sex diferansiasyonunda rol alan ve Transforming Growth Faktör-b ailesinin bir üyesidir. Kadında, gelişmekte olan follikülün granüloza hücreleri tarafından salgılanmakta olup, ovarian rezervin bir göstergesi olarak ortaya atılmıştır. Bizim çalışmamızda amaç, endometrioma stripping uygulanan hastalarda AMH seviyelerinde değişim olup olmadığının gösterilmesidir. Gereç ve yöntem: Çalışma GATA Kadın Hastalıkları ve Doğum AD da ovarian endometrima nedeni ile stripping uygulanan 47 hastayı içermektedir (Çalışmagrubu). Hastaların cerrahi öncesi endometrioma boyutları 45 mm ve üzerinde olan hastalardan seçilmiş olup, 33 hasta unilateral endometrioma ve 14 ü bilateral endometriomaya sahipti. Tüm hasta grubunda ovarian endometrioma stripping yöntemi laparoskopik olarak uygulanmıştır. Bulgular: Unilateral endometrioma ve bilateral endometrioma saptanan hastaların preoperatif AMH seviyeleri kontrol grubu ile karşılaştırıldığında gruplar arasında anlamlıfark saptanmamıştır (p: 0.98 vep: 0.71). Her 2 grup arasında istatistiksel olarak anlamlı fark saptanmamıştır (p:0.86). Sonuç: Sonuçlarımız göstermektedir ki, preoperatif AMH seviyeleri endometriomalı hastalarda folliküler havuzu değiştirici etki göstermemektedir. Kısa süreli izlemde ise, endometrioma stripping yöntemiAMH sekrete eden sağlıklı ovarian doku üzerinde hasar oluşturmamaktadır.

Anahtar Kelimeler

• -

Kaynakça

1. 1. Jenny A Vısser, FrankHde Jong, Joop SELavenl and Axel P N Themmen. Anti-Mullerian hormone: a new markerfor ovarianfunction. Reproduction, 2006, 131, l-9
2. 2. Annemarie G.M.G.J.Mulders, Joop S.E.Laven, Marinus J.C.Eijkemans, Frank H.de Jong, Axel P.N.Themmen andBart C.J.M.Fauser. Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility Human Reproduction, 2004, 19(9), 2036-2042
3. 3. Donnez J, Nisolle M, Gillet N, Smets M, Bassil S, Casanas-Roux F. Large ovarian endometriomas. Hum Reprod 1996,11, 641-646
4. 4. Hemmings R, Bissonnette F, Bouzayen R. Results of laparoscopic treatments of ovarian endometriomas: laparoscopic ovarian fenestration and coagulation. Fertil Steril 1998, 70, 527-529
5. 5. Bukman A and Heineman MJ, Ovarian reserve testing and the use of prognostic models in patients with subfertility. Hum Reprod Update, 2001, 7, 581-590
6. 6. Seifer DB, MacLaughlin DT, Christian BP, Feng B and Shelden RM, Early follicular serum mullerian-inhbiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril, 2002, 77, 468-471
7. 7. Gruijters MJG, Visser JA, Durlinger ALL and Themmen APN, Anti-Mullerian hormone and its role in ovarian function. Mol Cell Endocrinol, 2003, 211, 85-90
8. 8. Weenen C, Laven JS, Von Bergh AR, Crainfeld M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. 2004, 10(2), 77-83

9. 9. de Vet A, Laven JS, de Jong FH, Themmen AP and Fauser BC, Antimullerian hormone serum levels: aputative markerfor ovarian aging. Fertil Steril, 2002, 77, 357-362
10. 10. Fanchin R, Schonauer LM, Righini C, Frydman N,Frydman R and Taieb J,Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod, 2003, 18, 328-332